What happened in this Health story?

Trump administration officials, including CMS Administrator Mehmet Oz, claimed at a White House event that every U.S. state had agreed to join the GENEROUS federal drug pricing model for Medicaid — but officials in several states told STAT they're still undecided and weighing whether the deal beats existing drugmaker rebates.

What is a key fact in this story? (1)

**Trump administration** officials, including CMS Administrator **Mehmet Oz**, claimed at a White House event last Friday that every U.S. state had agreed to participate in the **GENEROUS model** drug pricing initiative for state Medicaid programs

What is a key fact in this story? (2)

**Oz** told the White House audience that "every state realized they need to take it" because the federal deal was such a strong one for Medicaid

📎 SkimNews has covered Trump administration 150+ times · see the file →

Trump's 'Every State' Drug Pricing Claim Overstated — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-09-24

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

Trump administration officials, including CMS Administrator Mehmet Oz, claimed at a White House event last Friday that every U.S. state had agreed to participate in the GENEROUS model drug pricing initiative for state Medicaid programs
Oz told the White House audience that "every state realized they need to take it" because the federal deal was such a strong one for Medicaid
Officials in several states told STAT they remain undecided on participation, even though they technically applied to the program
Some states are still trying to determine whether GENEROUS model pricing actually delivers better deals than the rebates they currently receive from drugmakers

Why it matters: State Medicaid programs that technically applied to GENEROUS told STAT they're still analyzing whether the federal pricing beats their existing drugmaker rebate arrangements — so the administration's "every state" framing overstates confirmed uptake. If a meaningful share of states ultimately decline, the Trump drug pricing initiative's Medicaid footprint will fall well short of the universal buy-in the White House portrayed.